Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Neurobiol Dis. 2010 May 20;39(3):409–422. doi: 10.1016/j.nbd.2010.05.013

Figure 2. Immunization with SDPM1 lowers amyloid plaque burden in APPswePSEN1(A246E) transgenic mice.

Figure 2

(A) SDPM1-specific antibody titers (total SDPM1 titer minus total SDPM2 titer) in APPswePSEN1(A246E) mice immunized once a month with SDPM1, SDPM2, or no peptide (Mock) beginning at 5 months of age and analyzed at 12 months of age (YOUNG), with or without adjuvant, or immunized beginning at 12 months of age and analyzed at 18 months of age (OLD) with adjuvant. (B) Breakdown of SDPM1-specific antibodies by subtype in SDPM1-immunized APPswePSEN1(A246E) mice (with adjuvant). (C) Antibody titers to Aβ1–42 amyloid for experiments described in A. (D) Hippocampus stained with Thioflavin S to visualize fibrillar Aβ amyloid in Young (12mo) and Old (18mo) immunized mice (with adjuvant) from A. Bar is 100µm. (E) Quantification of Aβ amyloid plaque burden as a percentage of total brain area in cortex and hippocampus. (F) Quantification of number of plaque profiles per unit area. (G) Quantification of average area per individual plaque. Errors are SEM for n=7–12 animals per condition, with n= 5–6 measurements per animal in A–C and 10–24 measurements per animal in E–G.